Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH3348 in Advanced Solid Tumors with c-Met Abnormalities
NCT05088070Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPH3348 in solid tumor (6 cohorts), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Dose-limiting toxicity at 24 days and Maximum tolerated dose at 24 days. Started Jul 2020; status: completed.
02
Drugs
SPH3348
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05088070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088070.